New Oral Drug SRN-901 Extends Mouse Lifespan by 33% and Cuts Tumor Risk
Seragon's SRN-901 outperformed rapamycin in aged mice, boosting median lifespan 33% and reducing frailty and tumor incidence.
Summary
Seragon Biosciences has published preclinical results showing its oral drug SRN-901 extended median remaining lifespan by 33% in aged mice eating a Western diet, outperforming rapamycin's 21% gain. The drug also reduced the statistical risk of death by 46%, slowed frailty progression by 70%, and cut tumor incidence by over 30%. Molecular analysis showed the drug activated DNA repair, improved energy metabolism, and dialed down inflammation and a key aging-related growth pathway called mTORC1. NMN and NR showed no significant lifespan benefit in the same study. SRN-901 is a multi-compound oral formulation taken daily, positioning it as a broad-spectrum longevity intervention rather than a single-target drug.
Detailed Summary
Seragon Biosciences has released preclinical data on SRN-901, a multi-target oral longevity drug, showing striking lifespan and healthspan benefits in aged mice. Published in Drug Design, Development and Therapy, the findings represent one of the more comprehensive longevity drug studies in recent memory, combining survival data with detailed molecular profiling.
The headline result: 18-month-old mice — roughly equivalent to late middle age in humans — fed a Western diet and treated with SRN-901 lived 33% longer on median than placebo controls. A Cox proportional hazards model, a standard statistical tool for survival analysis, found a 46% reduction in the hazard of death. For context, rapamycin — currently the gold standard longevity drug in mouse studies — achieved only a 21% median lifespan increase in the same trial. NMN and NR, popular longevity supplements, showed no significant lifespan benefit.
Beyond survival, SRN-901 slowed frailty progression by 70% relative to controls and reduced tumor incidence by 30.53%. These healthspan metrics matter because living longer without staying functional is not the goal of longevity medicine. The drug appears to compress morbidity as well as extend life.
At the molecular level, multi-omics profiling revealed upregulation of DNA repair pathways, energy metabolism, and stress resistance, alongside downregulation of inflammation, reactive oxygen species, apoptosis, and mTORC1 signaling — a pathway strongly linked to accelerated aging. This multi-pathway engagement is consistent with the drug's combinatorial design, which pairs longevity-associated compounds with Seragon's proprietary SRN-820 molecule.
Important caveats apply. This is mouse data from a company-sponsored study, and mouse-to-human translation in longevity research has a poor track record. The dose used — 500 mg/kg/day by oral gavage — is high and may not translate cleanly to human dosing. Independent replication and human trials are essential before drawing clinical conclusions.
Key Findings
- SRN-901 extended median remaining lifespan by 33% in aged Western-diet mice, outperforming rapamycin's 21% gain.
- Cox analysis showed a 46% reduction in hazard of death for SRN-901-treated mice versus placebo.
- Frailty progression slowed by 70% and tumor incidence dropped by 30.53% in treated animals.
- NMN and NR showed no significant lifespan benefit in the same controlled study.
- Multi-omics data showed reduced mTORC1, inflammation, and ROS alongside enhanced DNA repair and energy metabolism.
Methodology
This is a news report summarizing a company-sponsored preclinical study published in Drug Design, Development and Therapy, a peer-reviewed journal. The study used aged C57BL/6 mice with active comparator arms including rapamycin, NMN, and NR, with survival tracked until natural death. As a company-funded study, independent replication is needed to confirm findings.
Study Limitations
This is preclinical mouse data funded by the drug's developer, Seragon Biosciences, and has not been independently replicated. Mouse lifespan studies frequently fail to translate to humans, and the 500 mg/kg/day gavage dose may not reflect a feasible or safe human equivalent. Readers should consult the primary publication in Drug Design, Development and Therapy for full methodology and statistical details.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.